March 4 (Reuters) - Y-mAbs Therapeutics YMAB.O:
Y-MABS THERAPEUTICS Q4 PRODUCT REVENUE USD 26.5 MILLION
2025 ANTICIPATED TOTAL REVENUES EXPECTED TO BE BETWEEN $75 MILLION AND $90 MILLION
: CASH AND CASH EQUIVALENTS ANTICIPATED TO BE SUFFICIENT TO FUND OPERATIONS AS CURRENTLY PLANNED INTO 2027
OUTLOOK Q1 REVENUES EXPECTED TO BE BETWEEN $18 MILLION AND $21 MILLION
Q1 REVENUE VIEW $24.4 MILLION -- LSEG IBES DATA
FY2025 REVENUE VIEW $104.5 MILLION -- LSEG IBES DATA
: QTRLY LOSS PER SHARE $0.15
Q4 EARNINGS PER SHARE VIEW $-0.12, REVENUE VIEW $27.3 MILLION -- LSEG IBES DATA
Source text: ID:nGNX9cTcbF
Further company coverage: YMAB.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.